Hatteras Venture Partners

Founded 2000
Founders Clay B. Thorp John Crumpler

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 78
Average round size
info
The average size of a deal this fund participated in
$21M
Portfolio companies 46
Rounds per year 3.71
Lead investments 22
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.41
Exits 13
Key employees 6
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Medical Device
  • Therapeutics
Summary

Hatteras Venture Partners is the famous VC, which was founded in 2000. The venture was found in North America in United States. The main department of described VC is located in the Durham.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Hatteras Venture Partners, startups are often financed by Mountain Group Capital, Johnson & Johnson Development Corporation, Atlas Venture. The meaningful sponsors for the fund in investment in the same round are Fletcher Spaght, Inc., Excelerate Health Ventures, New Enterprise Associates. In the next rounds fund is usually obtained by Mountain Group Capital, OUP (Osage University Partners), New Enterprise Associates.

The fund has no exact preference in some founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline TetraLogic Pharmaceuticals, ORIG3N, Rodin Therapeutics Among the most popular fund investment industries, there are Medical, Therapeutics. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

The usual things for fund are deals in the range of 10 - 50 millions dollars. The top amount of exits for fund were in 2018. Comparing to the other companies, this Hatteras Venture Partners performs on 13 percentage points less the average number of lead investments. Speaking about the real fund results, this VC is 18 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 2-6 deals per year. The important activity for fund was in 2015. Despite it in 2019 the fund had an activity.

The current fund was established by Clay B. Thorp, John Crumpler. Besides them, we counted 12 critical employees of this fund in our database.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

GeneCentric Diagnostics

Biotechnology
Health Care
Health Diagnostics
$7M08 Nov 2021 Durham, North Carolina, United States

GoCheck

Health Care
Medical Device
Mobile Apps
$10M19 Oct 2021 Nashville, Tennessee, United States

Elligo Health Research

Biotechnology
Health Care
Medical
Pharmaceutical
$135M24 Sep 2021 Austin, Texas, United States

Vigil Neuroscience

Biotechnology
$90M18 Aug 2021 Cambridge, Massachusetts, United States

RapidPulse

Health Care
Medical Device
$15M23 Jun 2021 Miami, Florida, United States

Boston Immune Technologies & Therapeutics

Biotechnology
Therapeutics
$10M17 Mar 2021 -

StrideBio

Biotechnology
Health Care
Information Technology
Therapeutics
$81M16 Mar 2021 Durham, North Carolina, United States

Artizan Biosciences

Biopharma
Biotechnology
Life Science
$11M01 Mar 2021 New York, United States

Myeloid Therapeutics

Biotechnology
Life Science
$50M06 Jan 2021 Cambridge, Massachusetts, United States
News
Elligo Health Research Inks $135M Series E

– Elligo Health Research, a healthcare-enabling research organization powered by the novel IntElligo technology, announced a $135m Series E financing round.
Morgan Stanley Expansion Capital and Ally Bridge Group participated in the financing round.
– The round was also participated by Norwest Venture Partners and all major existing investors, including Cerner, Hatteras Venture Partners, Noro-Moseley Partners, Piper Sandler Merchant Banking, Shumway Capital, and Syneos Health.
– This financing allows Elligo to invest further in its technology platform and leverage data in new ways to address current challenges in the clinical trial industry.

Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases

– Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced the completion of a $90m Series B financing to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration.
– The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Hatteras Venture Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: